MYM Nutraceuticals
Market Cap
CA$25.9m
Last Updated
2021/01/18 23:07 UTC
Data Sources
Company Financials
Executive Summary
MYM Nutraceuticals Inc. cultivates, processes, and sells cannabis in Canada. More Details
Snowflake Analysis
Adequate balance sheet and overvalued.
Similar Companies
Share Price & News
How has MYM Nutraceuticals's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MYM is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 26% a week.
Volatility Over Time: MYM's weekly volatility has increased from 21% to 26% over the past year.
Market Performance
7 Day Return
22.2%
MYM
9.0%
CA Pharmaceuticals
0.2%
CA Market
1 Year Return
46.7%
MYM
47.4%
CA Pharmaceuticals
1.5%
CA Market
Return vs Industry: MYM matched the Canadian Pharmaceuticals industry which returned 46.7% over the past year.
Return vs Market: MYM exceeded the Canadian Market which returned 1.6% over the past year.
Shareholder returns
| MYM | Industry | Market | |
|---|---|---|---|
| 7 Day | 22.2% | 9.0% | 0.2% |
| 30 Day | 15.8% | 30.1% | 3.6% |
| 90 Day | 120.0% | 76.7% | 13.3% |
| 1 Year | 46.7%46.7% | 47.4%47.4% | 5.2%1.5% |
| 3 Year | -96.7%-96.7% | -52.9%-53.6% | 13.1%2.3% |
| 5 Year | 266.7%266.7% | 417.8%414.2% | 69.3%43.3% |
Long-Term Price Volatility Vs. Market
How volatile is MYM Nutraceuticals's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 months ago | Simply Wall St
Does MYM Nutraceuticals (CSE:MYM) Have A Healthy Balance Sheet?8 months ago | Simply Wall St
How Many MYM Nutraceuticals Inc. (CSE:MYM) Shares Did Insiders Buy, In The Last Year?9 months ago | Simply Wall St
What Kind Of Share Price Volatility Should You Expect For MYM Nutraceuticals Inc. (CSE:MYM)?Valuation
Is MYM Nutraceuticals undervalued compared to its fair value and its price relative to the market?
1.59x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MYM's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MYM's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MYM is unprofitable, so we can't compare its PE Ratio to the CA Pharmaceuticals industry average.
PE vs Market: MYM is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MYM's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MYM is good value based on its PB Ratio (1.6x) compared to the CA Pharmaceuticals industry average (2.7x).
Next Steps
Future Growth
How is MYM Nutraceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
60.3%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MYM Nutraceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine MYM Nutraceuticals's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- MYM Nutraceuticals competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has MYM Nutraceuticals performed over the past 5 years?
-59.4%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MYM is currently unprofitable.
Growing Profit Margin: MYM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MYM is unprofitable, and losses have increased over the past 5 years at a rate of 59.4% per year.
Accelerating Growth: Unable to compare MYM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MYM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-61.1%).
Return on Equity
High ROE: MYM has a negative Return on Equity (-99.41%), as it is currently unprofitable.
Next Steps
Financial Health
How is MYM Nutraceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: MYM's short term assets (CA$4.7M) exceed its short term liabilities (CA$3.3M).
Long Term Liabilities: MYM's short term assets (CA$4.7M) exceed its long term liabilities (CA$2.8M).
Debt to Equity History and Analysis
Debt Level: MYM's debt to equity ratio (16.7%) is considered satisfactory.
Reducing Debt: MYM's debt to equity ratio has reduced from 140.1% to 16.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MYM has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MYM has less than a year of cash runway if free cash flow continues to reduce at historical rates of 42.5% each year
Next Steps
Dividend
What is MYM Nutraceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MYM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MYM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MYM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MYM's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MYM's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.0yrs
Average management tenure
CEO
Michael Wiener
0.50
Tenure
Mr. Michael Wiener is Chief Executive Officer & Director at MYM Nutraceuticals Inc. since July 31, 2020. He has been an Executive Vice President and Chief Executive Officer of 35 Oak Holdings Limited since...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Financial Officer | 0.42yr | CA$733.70k | 0.60% CA$ 153.9k | |
| Executive VP | 3.17yrs | CA$191.63k | 0.45% CA$ 115.7k | |
| CEO & Director | 0.50yr | no data | 5.77% CA$ 1.5m | |
| Vice President of Operations | 1yr | no data | no data | |
| Vice President of Commercial Sales & Investor Relations | 1.92yrs | no data | no data | |
| Legal Counsel | 1yr | no data | no data | |
| Head of Sales | 1yr | no data | no data | |
| Executive Vice President of Corporate Services | 1yr | no data | no data | |
| Corporate Secretary | 0.33yr | no data | no data |
1.0yrs
Average Tenure
Experienced Management: MYM's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive VP | 3.17yrs | CA$191.63k | 0.45% CA$ 115.7k | |
| CEO & Director | 0.50yr | no data | 5.77% CA$ 1.5m | |
| Independent Non-Executive Chairman of the Board | 1.42yrs | CA$250.00k | 0.13% CA$ 32.4k | |
| Independent Director | 0.50yr | no data | 1.16% CA$ 300.0k | |
| Member of Advisory Board | 2.42yrs | no data | no data | |
| Independent Director | 2.67yrs | no data | 0.012% CA$ 3.2k |
1.9yrs
Average Tenure
60yo
Average Age
Experienced Board: MYM's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 54.5%.
Top Shareholders
Company Information
MYM Nutraceuticals Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: MYM Nutraceuticals Inc.
- Ticker: MYM
- Exchange: CNSX
- Founded: 2014
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$25.863m
- Shares outstanding: 246.32m
- Website: https://www.mym.ca
Number of Employees
Location
- MYM Nutraceuticals Inc.
- 409 West Pender Street
- Suite 1500
- Vancouver
- British Columbia
- V6E 2M6
- Canada
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MYM | CNSX (Canadian National Stock Exchange) | Yes | Common Shares | CA | CAD | Nov 2014 |
| 0MY | DB (Deutsche Boerse AG) | Yes | Common Shares | DE | EUR | Nov 2014 |
| MYMM.F | OTCPK (Pink Sheets LLC) | Yes | Common Shares | US | USD | Nov 2014 |
Biography
MYM Nutraceuticals Inc. cultivates, processes, and sells cannabis in Canada. The company was formerly known as My Marijuana Canada Inc. and changed its name to MYM Nutraceuticals Inc. in February 2016. MYM...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/18 23:07 |
| End of Day Share Price | 2021/01/18 00:00 |
| Earnings | 2020/08/31 |
| Annual Earnings | 2020/05/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.